Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 601–685 of 685
Shamchuk, A. L., Doulla, M., & Jetha, M. M. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.202627-f
[Diabetes and oral contraceptives].
Aragón, J. A. V., & González, E. L. D. L. O. (1974) · PubMed
SGLT2阻害薬内服下で甲状腺クリーゼとeuglycemic DKAを併発した1例
櫃割, 拓., 鶴谷, 悠., 洲之内, 尭., Horikoshi, H., 山根, 貴., 廣瀬, 玲., 星野, 良., 渡邊, 智., 桂川, 翔., & 齋藤, 淳. (2021) · Folia Endocrinologica Japonica · doi:10.1507/endocrine.97.s.update_34
Solhjou, Z., & McGrath, M. M. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2022.20.2.5
Lu, H. Y., Hullin, R., Yerly, P., Meyer, P., Kosinski, C., & Daux, A. (2021) · JMIG · doi:10.53738/revmed.2021.17.740.1034
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
SGLT2 Inhibitors and the Associated Risk of Genito Mycotic Infections – A Narrative Review
Sharanya Shre, E. S. (2022) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v5-i5-13
Magbri, A., El-Magbri, E., El-Magbri, M., Brar, B., & Rashid, S. (2019) · Arabixiv (OSF Preprints) · doi:10.31221/osf.io/f4xub
Magbri, A., El-Magbri, E., El-Magbri, M., Brar, B., & Rashid, S. (2019) · INA-Rxiv (OSF Preprints) · doi:10.31227/osf.io/zbw26
How do I diagnose and manage acute endocrine emergencies in the ICU?
Fernandez-Moure, J. S., Whitlock, A. E. G., & Sims, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64068-8.00081-x
Aschner, P. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727299606.793538292
Schwere Blutzuckerentgleisungen
Reitgruber, D., & Auer, J. (2021) · Internistische Intensivmedizin für Einsteiger · doi:10.1007/978-3-662-61823-3_39
Gilbert, M. P., & SHAH, A. S. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407663.case16
Ketoacidosis Without Significantly Hyperglycaemia - Is It Possible?
Budzyński, M., Pekar, J., Skolarczyk, J., Tadla, M., & Skórzyńska-Dziduszko, K. (2017) · Journal of Education, Health and Sport (Kazimierz Wielki University in Bydgoszcz) · doi:10.5281/zenodo.804618
Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus
Mukhopadhyay, J. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.20.3.0371
“These lower levels of glucose make diagnosis of euDKA more difficult and may lead to delayed treatment (27).”
BackgroundInfluentialYasser, S., & Hesham, M. (2022) · American Journal of Chemistry and Pharmacy · doi:10.54536/ajcp.v1i2.747
Dapagliflozin and euglycaemic diabetic ketoacidosis – ‘But doctor my sugars were normal!’
Watters, K., Greener, V., Theodoraki, A., Nogueira, E. F., & Shotliff, K. (2022) · Practical Diabetes · doi:10.1002/pdi.2430
Obesity - Recent Insights and Therapeutic Options
McFarlane, S. I. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104318
A Case of SGLT-2i Induced Euglycemic Diabetic Ketoacidosis in the Setting of Gastrointestinal Stress
Reddy, G., Tailor, A., & Tanase, A. (2022) · doi:10.51521/ijdcr.2022.1101
“In euDKA, insulin deficiency and resistance are milder compared to standard DKA, hence, glucose overproduction and underutilization are less [5].”
BackgroundSession Three: Innovating Beyond Glucose Control in Diabetes Care
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10314488
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_36
SGLT2 Inhibitors in the Prevention and Treatment of Cardiovascular Disease
Rheaume, M., Khetan, A. K., & Pigeyre, M. (2023) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v17isp2.684
Nakajima, H., Okada, H., Yoshimura, Y., Tanaka, T., Hasegawa, G., Mitsuhashi, K., Kitagawa, N., Okamura, T., Hashimoto, Y., Senmaru, T., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15262
“The fact that SGLT2i increased the risk of normoglycaemic ketoacidosis, as previously reported 18,19 should be considered because the TIR increased after SGLT2i Our results indicate that patients whose ketones had been elevated before the start of SGLT2i would probably develop ketone elevations…”
ResultShubrook, J. H., Neumiller, J. J., Alicic, R. Z., Manley, T., & Tuttle, K. R. (2023) · Diabetology · doi:10.3390/diabetology4040039
“Euglycemic diabetic ketoacidosis (DKA) may occur in patients taking SGLT-2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion [46,47].”
BackgroundMESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1
Litwak, L., Martín, C. G., Garrido, N., Koleff, C. K., Canda, M. E., Burgos, M. A., Bertollo, N., Scaliti, M. G., Blanco, M. A., Calvo, M. L., et al. (2015) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v49i3.633
Pilianidis, G., Papanastasiou, G., Tikoudi, P., Themistocleous, A. C., Farmakis, G., & Dolianitis, K. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004282
“If euglycemic DKA is detected then it can be prevented and alleviated by maintaining fluid and carbohydrate intake, and by stopping SGLT2 inhibitors [7] .”
BackgroundAhmedana, S. E., Mansour, M. B., & Basheer, A. M. (2024) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2024.95257631
Drago, T. J., Wadid, M., Brodeur, P. G., Palatnic, L., Najam, U. S., Bharucha, R., Moyer, R. R., Monte, A., Miranda, C. J., Drago, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(24)02485-9
Gliflozins - what's new in practise
Škrha, J. (2024) · Medicína pro praxi · doi:10.36290/med.2024.012
Postoperative Euglycemic Diabetic Ketoacidosis
Anand, S. (2024) · Indian Journal of Critical Care Case Report · doi:10.5005/jp-journals-11006-0121
Küçükbezirci, H. F. (2024) · doi:10.5152/9902
Akut Karaciğer Yetmezliği ve Hepatik Ensefalopati
Aman, G. (2024) · doi:10.5152/9912
Çirkin, Y., & Özkan, S. (2024) · doi:10.5152/9919
Gün, M. (2024) · doi:10.5152/9923
KIYAK, S. K. (2024) · doi:10.5152/9917
Küçükbezirci, H. F., & ÇAKMAK, F. (2024) · doi:10.5152/9918
ÖZKAN, S. (2024) · doi:10.5152/9901
Kanbakan, A. (2024) · doi:10.5152/9905
Özkan, S. (2024) · doi:10.5152/9922
Akut Böbrek Yetmezliği (Akut Böbrek Hasarı)
KIYAK, S. K. (2024) · doi:10.5152/9913
Crush Yaralanma (Ezilme Sendromu) ve Rabdomiyoliz
İPEKCI, A. (2024) · doi:10.5152/9909
KIYAK, S. K. (2024) · doi:10.5152/9908
DEMIRTAKAN, T. (2024) · doi:10.5152/9915
Aman, G. (2024) · doi:10.5152/9906
Akut İskemik İnme ve Geçici İskemik Atak
KIYAK, S. K. (2024) · doi:10.5152/9916
Diagnostik und Therapie der Diabetischen Ketoazidose bei Erwachsenen
Meitner-Schellhaas, B., & Haak, T. (2024) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-024-00243-5
“Patienten unter Therapie mit SGLT2-Hemmernmüssendarüberaufgeklärtsein, die Therapie bei akuten Infekten, Stress-Ereignissen, operativen Eingriffen, Fasten-perioden oder anderen Zuständen mit der Gefahr der Katabolie zu pausieren (soge-nannte „sick day rules“) [15–17].”
Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
Winciorek, J., Cyran, P., Jaroszyńska, A., Jaroszyński, F., Kowal, J., Paleczny, J., Parobczak, R., Połujański, P., & Wiśniewska, A. M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.68.55325
“[29] Figure 2.”
Steenkamp, D. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch08
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_3
A Case of Euglycemic Diabetic Ketoacidosis in a Patient with Diabetic Foot Syndrome
GIAMBALVO, M., Giangreco, F., Iacopi, E., Pieruzzi, L., Goretti, C., & Piaggesi, A. (2025) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346241308120
Meraj, A., & Herbert, A. (2025) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2025.143014
Euglycemic diabetic ketoacidosis of unknown Etiology in a type 2 diabetic patient
Villegas, K. J., Guerrero, L., Moussa, H., Rajab, I. M., Rezkalla, A. M., Patel, D., & Qarqash, M. A. (2025) · Oxford Medical Case Reports · doi:10.1093/omcr/omaf057
Altom, S. A. A., Alhajri, A. H. M., Ali, H. K. M., Ahmed, D. A. M., Rahma, M. A. R., Ahmed, T. A. M., Alatif, M. M. M. A., & AHMED, R. (2025) · Cureus · doi:10.7759/cureus.93456
“This aligns with existing literature, emphasizing the role of SGLT2i in promoting ketogenesis through increased glucagon secretion and reduced insulin-mediated suppression of lipolysis, even in the absence of hyperglycemia [21,22].”
Shah, A. D., Hebbale, V. A., Sarda, P., & Khobragade, K. J. (2025) · International Journal of Scientific Reports · doi:10.18203/issn.2454-2156.intjscirep20253330
Metabolic Acidosis in Chronic Alcoholism: When It’s Not Just Diabetic Ketoacidosis
Li, R., Han, J., & Sidhu, H. (2025) · Cureus · doi:10.7759/cureus.96632
“Despite commonly presenting with ketosis and anion gap metabolic acidosis, DKA, AKA, and euDKA are fundamentally different in their pathophysiology, risk factors, and treatment [3,4].”
Diabetic emergencies and glucose control in the ICU
Ramanan, M., & Ekinci, E. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00068-2
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Castaneda, L., & Sarkisyan, D. (2024) · eScholarship (California Digital Library)
(n.d.) · RWTH Publications (RWTH Aachen)
Tratamiento de la diabetes en gatos: estudio de la velagliflozina
Amalbert de Prado, P., Mesonero Gutiérrez, J. E., & Martí Jimenez, J. I. (2025) · Zaguan (Universidad de Zaragoza)
Navarrete, R. E. T., Fernandes, J., Fonseca, I. M., Silvano, J., Martins, L. S., & Sa, J. R. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100302
Stanley, T. L. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_6
Farley, T. M., & Nezirevic, S. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.05.004
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Yong, C. (2026) · Nature Communications · doi:10.1038/s41467-026-72947-y
Efectos de la dapaglifozina en la enfermedad renal diabética más allá del control glucémico
Vinces, M., Salas, A., Paoli, M., Molina, K., Pérez, J., & Salas, G. (2025) · Revista Venezolana de Endocrinología y Metabolismo · doi:10.53766/rvem/2025.23.2.05
Safety profile of empagliflozin in clinical practice: A scoping review of real-world evidence
Malwatta, M. A. L. D., Wasana, P. W. D., & Gunawardena, S. (2026) · Asian Journal of Medical Sciences · doi:10.71152/ajms.v17i6.5296
Unwin, R. J., Challis, B., Wagner, C. A., Capasso, G., & Carlsson, S. (2026) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-026-03184-x
“…ketoacidosis with SGLT2 inhibitors, arising from effects on insulin, glucagon, and hepatic ketogenesis in those with underlying beta-cell failure, illustrates how early mechanistic insights can support risk mitigation and patient selection before extensive safety datasets are available [34].”
Kardiometabolisches Syndrom – Pathophysiologie, Therapie und Prävention
Raeder, S. (2026) · Kardiologie up2date · doi:10.1055/a-2654-6802
Zhu, Y., Wang, Y., Zhang, M., Liu, L., Tian, Y., Guo, Z., Zhang, R., Zhang, J., Ma, Z., 方福德, et al. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026117
Euglycemic ketoacidosis following sleeve gastrectomy in a young non-diabetic female: a case report
Kor, F. (2026) · International Journal of Surgery Case Reports · doi:10.1097/rc9.0000000000000675
“Patient education on maintaining adequate caloric intake and hydration post-surgery is critical to prevent EKA [ 6 , 11 ] .”
InfluentialEthanol as a Modifier of Drug Toxicity in Humans: Pathways of Toxicity and Organ-Level Consequences
Bukowska, B., Bukowski, K., & Broncel, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146270
Euglycemic Ketoacidosis: An Overlap of Diabetic and Non-diabetic Causes
Madu, A., & Garg, H. (2026) · Acta Medica Academica · doi:10.5644/ama2006-124.513
“They also inhibit ketonuria and directly stimulate pancreatic alpha cells to secrete glucagon (5, 6).”
Merilyn Xie, H., Lacroix, M., Lyashchenko, A. K., & Cremers, S. (2026) · doi:10.22541/authorea.15006455/v1
Sergejuk, E., Kotlarski, W., Kotlarska, K. M., & Mainka, T. S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5543
“Ketone bodies become an energy substrate for cells, partially replacing glucose in this function, as it cannot be transported inside the cell due to the lack of insulin (Rosenstock & Ferrannini, 2015).”
SGLT2 Inhibitors in Type 1 Diabetes: The Metabolic Perspective
Hamidi, V., & Mudaliar, S. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_825
Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report
Reyes, J. C. S., Carrillo, M. F., Jaen, R. L., & Batista, A. J. (2026) · Cureus · doi:10.7759/cureus.114492 · Cited by 1
“Although serum beta-hydroxybutyrate measurements were unavailable, the combination of metabolic acidosis, ketonuria, and mild hyperglycemia remained consistent with previously described diagnostic features of euDKA [2,6-9].”
Durma, A. C., Blicharska, M., & Czupryniak, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01913-0 · Cited by 1
“A rare but serious adverse event is euglycaemic diabetic ketoacidosis (euDKA), which is character‑ ised by metabolic acidosis and ketosis with normal or only mildly elevated blood glucose [64].”
Chen, J., Wang, D., Duan, X., Wang, J., Zhao, Z., & Xing, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1957734
“The pattern is coherent with the established pharmacology of SGLT-2 inhibition: blocking SLC5A2 induces persistent glucosuria, and the resulting fall in plasma glucose lowers insulin and raises the glucagon-to-insulin ratio (7, 25).”
SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
Grujic-Milanovic, J., Rajković, J., Novaković, R., Sharifi‐Rad, J., & Călina, D. C. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70204
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
Ferrannini, E. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_824
Self-citationPrise en charge thérapeutique du diabète de type 2
Rigalleau, V., Cherifi, B., Blanco, L., Larroumet, A., Foussard, N., & Mohammedi, K. (2026) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(26)50825-1
Ji, K., Zhang, D., Zhao, Y., Zeng, Z., Jiang, M., & Zhang, J. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101793
Jarrar, I., Masri, H., & Al-Ahmad, S. (2026) · AAUP Journal of STEM and Health Sciences · doi:10.35517/jsh-aaup.v1.02.07
Long, B., Eddy, E., Sandei, T., & Meyer, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00650-3
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.